We evaluated the interferon-free combination of the protease inhibitor ABT-450 with ritonavir ( ABT-450 / r ) , the NS5A inhibitor ombitasvir ( ABT-267 ) , the nonnucleoside polymerase inhibitor dasabuvir ( ABT-333 ) , and ribavirin in an open-label phase 3 trial involving previously untreated and previously treated adults with HCV genotype 1 infection and compensated cirrhosis .